Published in Pediatr Surg Int on February 17, 2006
Reversible ceftriaxone-associated biliary pseudolithiasis in children. Lancet (1988) 2.33
Transient formation of precipitations in the gallbladder associated with ceftriaxone therapy. Pediatr Infect Dis (1987) 1.92
Ceftriaxone-associated gallbladder sludge. Identification of calcium-ceftriaxone salt as a major component of gallbladder precipitate. Gastroenterology (1991) 1.66
Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs (1984) 1.65
Pharmacokinetic profile of ceftriaxone in man. Am J Med (1984) 1.58
Biliary colic: Is it gallstones? J Paediatr Child Health (2005) 1.50
Pathogenesis of ceftriaxone-associated biliary sludge. In vitro studies of calcium-ceftriaxone binding and solubility. Gastroenterology (1990) 1.34
Pharmacokinetics of ceftriaxone following intravenous administration of a 3 g dose. Eur J Clin Pharmacol (1982) 1.27
Ceftriaxone-associated nephrolithiasis and biliary pseudolithiasis in a child. Pediatr Radiol (2003) 1.21
Early biliary pseudolithiasis during ceftriaxone therapy for acute pyelonephritis in children: a prospective study in 34 children. Eur J Pediatr Surg (2000) 1.17
Sonographic assessment of ceftriaxone-associated biliary pseudolithiasis in children. J Clin Ultrasound (2000) 1.08
Incidence of ceftriaxone-associated gallbladder pseudolithiasis. Acta Paediatr (1999) 1.01
Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis. Am J Gastroenterol (1991) 0.99
Ceftriaxone-associated cholecystitis. Pediatr Infect Dis J (1988) 0.98
Ceftriaxone-associated biliary sludge and pseudocholelithiasis during childhood: a prospective study. Pediatr Int (2004) 0.96
Concentrative biliary secretion of ceftriaxone. Inhibition of lipid secretion and precipitation of calcium ceftriaxone in bile. Gastroenterology (1990) 0.93
Ceftriaxone-induced cholelithiasis. Ann Intern Med (1991) 0.92
The influence of third-generation cephalosporins on the aerobic intestinal flora. Infection (1985) 0.90
Ceftriaxone-associated biliary pseudolithiasis in adults. Lancet (1989) 0.89
Biliary pseudolithiasis in a child associated with 2 days of ceftriaxone therapy. Pediatr Radiol (1994) 0.88
Ceftriaxone-associated biliary pseudolithiasis in children. Eur Radiol (2001) 0.87
Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy. AJR Am J Roentgenol (1992) 0.87
Ceftriaxone choledocholithiasis. Pediatrics (1996) 0.85
High biliary elimination of ceftriaxone in man. Int J Clin Pharmacol Ther Toxicol (1988) 0.83
Apparent biliary pseudolithiasis during ceftriaxone therapy. Antimicrob Agents Chemother (1990) 0.83
Ceftriaxone and reversible cholelithiasis. BMJ (1988) 0.81
Iatrogenic gallstones: a ceftriaxone complication. Australas Radiol (1998) 0.77
Ceftriaxone and biliary pseudolithiasis. Pediatr Infect Dis J (1988) 0.77
Biliary excretion of ceftriaxone. Eur J Clin Pharmacol (1986) 0.77
Ceftriaxone-associated gallbladder lithiasis in children. Eur J Pediatr (1995) 0.77
Gallstone pancreatitis caused by ceftriaxone. Pediatr Infect Dis J (1998) 0.77
Genetic interaction of PGE2 and Wnt signaling regulates developmental specification of stem cells and regeneration. Cell (2009) 4.69
A.S.P.E.N. clinical guidelines: nutrition support of neonatal patients at risk for necrotizing enterocolitis. JPEN J Parenter Enteral Nutr (2012) 3.42
Partial hepatectomy in the mouse: technique and perioperative management. J Invest Surg (2003) 2.07
Safety and efficacy of a fish-oil-based fat emulsion in the treatment of parenteral nutrition-associated liver disease. Pediatrics (2008) 2.02
APC mutant zebrafish uncover a changing temporal requirement for wnt signaling in liver development. Dev Biol (2008) 1.90
Parenteral fish oil improves outcomes in patients with parenteral nutrition-associated liver injury. Ann Surg (2009) 1.90
Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat Med (2004) 1.70
Pediatric anorectal impalement with bladder rupture: case report and review of the literature. J Pediatr Surg (2006) 1.69
Provision of a soy-based intravenous lipid emulsion at 1 g/kg/d does not prevent cholestasis in neonates. JPEN J Parenter Enteral Nutr (2012) 1.64
Reversal of parenteral nutrition-associated liver disease in two infants with short bowel syndrome using parenteral fish oil: implications for future management. Pediatrics (2006) 1.60
The role of an intravenous fat emulsion composed of fish oil in a parenteral nutrition-dependent patient with hypertriglyceridemia. Nutr Clin Pract (2007) 1.52
Analysis of tumor-associated stromal cells using SCID GFP transgenic mice: contribution of local and bone marrow-derived host cells. FASEB J (2006) 1.52
A.S.P.E.N. Clinical Guidelines: hyperglycemia and hypoglycemia in the neonate receiving parenteral nutrition. JPEN J Parenter Enteral Nutr (2011) 1.41
Newborn and toddler intestinal obstruction owing to congenital mesenteric defects. J Pediatr Surg (2008) 1.38
Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin. Cancer Cell (2005) 1.37
Endothelial-directed hepatic regeneration after partial hepatectomy. Ann Surg (2003) 1.34
Omega-3 fatty acid supplementation prevents hepatic steatosis in a murine model of nonalcoholic fatty liver disease. Pediatr Res (2005) 1.33
Microdeformational wound therapy: effects on angiogenesis and matrix metalloproteinases in chronic wounds of 3 debilitated patients. Ann Plast Surg (2006) 1.30
Fish oil-based lipid emulsions prevent and reverse parenteral nutrition-associated liver disease: the Boston experience. JPEN J Parenter Enteral Nutr (2009) 1.25
Prevention of parenteral nutrition-associated liver disease: role of omega-3 fish oil. Curr Opin Organ Transplant (2010) 1.18
Dietary fat intake promotes the development of hepatic steatosis independently from excess caloric consumption in a murine model. Metabolism (2010) 1.15
Current clinical applications of omega-6 and omega-3 fatty acids. Nutr Clin Pract (2006) 1.10
Use of a fish oil-based lipid emulsion to treat essential fatty acid deficiency in a soy allergic patient receiving parenteral nutrition. Clin Nutr (2005) 1.10
The essentiality of arachidonic acid and docosahexaenoic acid. Prostaglandins Leukot Essent Fatty Acids (2009) 1.08
Epoxyeicosanoids promote organ and tissue regeneration. Proc Natl Acad Sci U S A (2013) 1.08
Prolonging the female reproductive lifespan and improving egg quality with dietary omega-3 fatty acids. Aging Cell (2012) 1.04
Parenteral fish-oil-based lipid emulsion improves fatty acid profiles and lipids in parenteral nutrition-dependent children. Am J Clin Nutr (2011) 1.04
Ablation of leptin signaling disrupts the establishment, development, and maintenance of endometriosis-like lesions in a murine model. Endocrinology (2007) 1.02
Comparison of 5 intravenous lipid emulsions and their effects on hepatic steatosis in a murine model. J Pediatr Surg (2011) 0.98
Inhibition of matrix metalloproteinases increases PPAR-alpha and IL-6 and prevents dietary-induced hepatic steatosis and injury in a murine model. Am J Physiol Gastrointest Liver Physiol (2006) 0.97
Aspartate aminotransferase to platelet ratio index correlates with hepatic cirrhosis but not with fibrosis in pediatric patients with intestinal failure. J Pediatr Gastroenterol Nutr (2013) 0.97
Vascular endothelial growth factor accelerates compensatory lung growth after unilateral pneumonectomy. Am J Physiol Lung Cell Mol Physiol (2006) 0.96
Omega-3 fatty acids improve hepatic steatosis in a murine model: potential implications for the marginal steatotic liver donor. Transplantation (2005) 0.96
Broad-spectrum matrix metalloproteinase inhibition curbs inflammation and liver injury but aggravates experimental liver fibrosis in mice. PLoS One (2010) 0.96
The route of lipid administration affects parenteral nutrition-induced hepatic steatosis in a mouse model. J Pediatr Surg (2005) 0.93
Endothelial progenitor cells contribute to accelerated liver regeneration. J Pediatr Surg (2007) 0.93
Pneumonectomy in the mouse: technique and perioperative management. J Invest Surg (2005) 0.92
Prevention of intra-abdominal adhesions using the antiangiogenic COX-2 inhibitor celecoxib. Ann Surg (2005) 0.92
The prevention and treatment of intestinal failure-associated liver disease in neonates and children. Surg Clin North Am (2011) 0.91
Omega-3 fatty acids and liver disease. Hepatology (2007) 0.91
Sunitinib inhibits postoperative adhesions in a rabbit model. Surgery (2011) 0.90
Intravenous fish oil lipid emulsion promotes a shift toward anti-inflammatory proresolving lipid mediators. Am J Physiol Gastrointest Liver Physiol (2013) 0.88
Parenteral fish oil monotherapy in the management of patients with parenteral nutrition-associated liver disease. Arch Surg (2010) 0.88
Fish oil prevents essential fatty acid deficiency and enhances growth: clinical and biochemical implications. Metabolism (2008) 0.88
Effects of metalloproteinase inhibition in a murine model of renal ischemia-reperfusion injury. Pediatr Res (2010) 0.88
Pediatric rib lesions: a 13-year experience. J Pediatr Surg (2008) 0.87
Reduction of hepatocellular injury after common bile duct ligation using omega-3 fatty acids. J Pediatr Surg (2008) 0.87
A critical role for matrix metalloproteinases in liver regeneration. J Surg Res (2008) 0.87
Parenteral fish oil as monotherapy prevents essential fatty acid deficiency in parenteral nutrition-dependent patients. J Pediatr Gastroenterol Nutr (2010) 0.87
Innovative parenteral and enteral nutrition therapy for intestinal failure. Semin Pediatr Surg (2010) 0.86
Repetitive orogastric gavage affects the phenotype of diet-induced obese mice. Physiol Behav (2010) 0.86
Treatment of parenteral nutrition-associated liver disease: the role of lipid emulsions. Adv Nutr (2013) 0.86
Parenteral fish oil as monotherapy improves lipid profiles in children with parenteral nutrition-associated liver disease. JPEN J Parenter Enteral Nutr (2010) 0.86
Acid sphingomyelinase involvement in tumor necrosis factor alpha-regulated vascular and steroid disruption during luteolysis in vivo. Proc Natl Acad Sci U S A (2008) 0.85
Docosahexaenoic acid and arachidonic acid prevent essential fatty acid deficiency and hepatic steatosis. JPEN J Parenter Enteral Nutr (2011) 0.85
Do polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREPB-1 suppression or by correcting essential fatty acid deficiency. Hepatology (2004) 0.84
The growing role of eicosanoids in tissue regeneration, repair, and wound healing. Prostaglandins Other Lipid Mediat (2013) 0.82
A metabolomic analysis of two intravenous lipid emulsions in a murine model. PLoS One (2013) 0.82
Tissue-specific differences in inflammatory infiltrate and matrix metalloproteinase expression in adipose tissue and liver of mice with diet-induced obesity. Hepatol Res (2012) 0.82
The role of the ω-3 fatty acid DHA in the human life cycle. JPEN J Parenter Enteral Nutr (2012) 0.81
The effect of varying ratios of docosahexaenoic acid and arachidonic acid in the prevention and reversal of biochemical essential fatty acid deficiency in a murine model. Metabolism (2012) 0.81
Tumor necrosis factor α-converting enzyme inhibition reverses hepatic steatosis and improves insulin sensitivity markers and surgical outcome in mice. PLoS One (2011) 0.81
Purified fish oil eliminating linoleic and alpha linolenic acid meets essential fatty acid requirements in rats. Metabolism (2012) 0.80
Fish oil-based lipid emulsion in the treatment of parenteral nutrition-associated liver disease. Curr Opin Pediatr (2013) 0.80
Inhibition of neuroblastoma cell proliferation with omega-3 fatty acids and treatment of a murine model of human neuroblastoma using a diet enriched with omega-3 fatty acids in combination with sunitinib. Pediatr Res (2011) 0.80
Cholestasis and growth in neonates with gastroschisis. J Pediatr Surg (2012) 0.80
The natural history of cirrhosis from parenteral nutrition-associated liver disease after resolution of cholestasis with parenteral fish oil therapy. Ann Surg (2015) 0.80
Effects of glucose or fat calories in total parenteral nutrition on fat metabolism and systemic inflammation in rats. Metabolism (2010) 0.79
Impact of fish oil-based lipid emulsion on serum triglyceride, bilirubin, and albumin levels in children with parenteral nutrition-associated liver disease. Pediatr Res (2009) 0.79
A.S.P.E.N. clinical guidelines: nutrition support of neonatal patients at risk for metabolic bone disease. JPEN J Parenter Enteral Nutr (2013) 0.79
Dietary fish oil aggravates paracetamol-induced liver injury in mice. JPEN J Parenter Enteral Nutr (2012) 0.78
Prenatal diagnosis and subsequent treatment of an intermediate-risk paraspinal neuroblastoma: case report and review of the literature. Fetal Diagn Ther (2008) 0.78
A tutorial on fatty acid biology. JPEN J Parenter Enteral Nutr (2012) 0.77
Inhibition of intra-abdominal adhesion formation with the angiogenesis inhibitor sunitinib. J Surg Res (2007) 0.77
Sunitinib reduces recurrent pelvic adhesions in a rabbit model. J Surg Res (2012) 0.77